Persistent episomal transgene expression in liver following delivery of a scaffold/matrix attachment region containing non-viral vector

被引:76
作者
Argyros, O. [1 ]
Wong, S. P. [2 ]
Niceta, M. [2 ]
Waddington, S. N. [3 ]
Howe, S. J. [4 ]
Coutelle, C. [2 ]
Miller, A. D. [1 ,5 ]
Harbottle, R. P. [1 ,2 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Imperial Coll Genet Therapies Ctr, Dept Chem, London SW7 2AZ, England
[2] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Sect Mol Med, Gene Therapy Res Grp, London SW7 2AZ, England
[3] Royal Free & Univ Coll Med Sch, Mol Dept Haematol, Haemophilia Ctr & Haemostasis Unit, London WC1E 6BT, England
[4] UCL, Inst Child Hlth, Mol Immunol Unit, London, England
[5] ImuThes Ltd, London, England
基金
英国医学研究理事会;
关键词
persistent expression; episomal maintenance; S/MAR plasmid; hydrodynamic delivery;
D O I
10.1038/gt.2008.113
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
An ideal gene therapy vector should enable persistent transgene expression without limitations of safety and reproducibility. Here we report the development of a non-viral episomal plasmid DNA (pDNA) vector that appears to fulfil these criteria. This pDNA vector combines a scaffold/matrix attachment region (S/MAR) with a human liver-specific promoter (alpha 1-antitrypsin (AAT)) in such a way that long-term expression is enabled in murine liver following hydrodynamic injection. Long-term expression is demonstrated by monitoring the longitudinal luciferase expression profile for up to 6 months by means of in situ bioluminescent imaging. All relevant control pDNA constructs expressing luciferase are unable to sustain significant transgene expression beyond 1 week post-administration. We establish that this shutdown of expression is due to promoter methylation. In contrast, the S/MAR element appears to inhibit methylation of the AAT promoter thereby preventing transgene silencing. Although this vector appears to be maintained as an episome throughout, we have no evidence for its establishment as a replicating entity. We conclude that the combination of a mammalian, tissue-specific promoter with the S/MAR element is sufficient to drive long-term episomal pDNA expression of genes in vivo.
引用
收藏
页码:1593 / 1605
页数:13
相关论文
共 49 条
  • [1] Evaluation of viral and mammalian promoters for driving transgene expression in mouse liver
    Al-Dosari, M
    Zhang, GS
    Knapp, JE
    Liu, DX
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 339 (02) : 673 - 678
  • [2] Long-term therapeutic levels of human alpha-1 antitrypsin in plasma after hydrodynamic injection of nonviral DNA
    Aliño, SF
    Crespo, A
    Dasí, F
    [J]. GENE THERAPY, 2003, 10 (19) : 1672 - 1679
  • [3] An araC-controlled bacterial cre expression system to produce DNA minicircle vectors for nuclear and mitochondrial gene therapy
    Bigger, BW
    Tolmachov, O
    Collombet, JM
    Fragkos, M
    Palaszewski, I
    Coutelle, C
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (25) : 23018 - 23027
  • [4] Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle
    Brooks, AR
    Harkins, RN
    Wang, PY
    Qian, HS
    Liu, PX
    Rubanyi, GM
    [J]. JOURNAL OF GENE MEDICINE, 2004, 6 (04) : 395 - 404
  • [5] Stem cell-derived erythroid cells mediate long-term systemic protein delivery
    Chang, Alex H.
    T Stephan, Matthias
    Sadelain, Michel
    [J]. NATURE BIOTECHNOLOGY, 2006, 24 (08) : 1017 - 1021
  • [6] A lentiviral vector encoding the human Wiskott Aldrich syndrome protein corrects immune and cytoskeletal defects in WASP knockout mice
    Charrier, S
    Stockholm, D
    Seye, K
    Opolon, P
    Taveau, M
    Gross, DA
    Bucher-Laurent, S
    Delenda, C
    Vainchenker, W
    Danos, O
    Galy, A
    [J]. GENE THERAPY, 2005, 12 (07) : 597 - 606
  • [7] Improved production and purification of minicircle DNA vector free of plasmid bacterial sequences and capable of persistent transgene expression in vivo
    Chen, ZY
    He, CY
    Kay, MA
    [J]. HUMAN GENE THERAPY, 2005, 16 (01) : 126 - 131
  • [8] Gene therapy progress and prospects: Episomally maintained self-replicating systems
    Conese, M
    Auriche, C
    Ascenzioni, F
    [J]. GENE THERAPY, 2004, 11 (24) : 1735 - 1741
  • [9] Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies
    Cordier, L
    Gao, GP
    Hack, AA
    McNally, EM
    Wilson, JM
    Chirmule, N
    Sweeney, HL
    [J]. HUMAN GENE THERAPY, 2001, 12 (02) : 205 - 215
  • [10] Minicircle:: an improved DNA molecule for in vitro and in vivo gene transfer
    Darquet, AM
    Rangara, R
    Kreiss, P
    Schwartz, B
    Naimi, S
    Delaère, P
    Crouzet, J
    Scherman, D
    [J]. GENE THERAPY, 1999, 6 (02) : 209 - 218